Trial Profile
Phase 1/2a, dose-escalation, safety and proof of concept study of intravesical DTA-H19 [BC 819] in patients with superficial bladder cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Proof of concept
- 04 Jan 2008 Status changed from in progress to completed.
- 27 Jun 2007 Status changed from recruiting to in progress.
- 12 Nov 2006 New trial record.